NCT01137591

Brief Summary

The purpose of this study is to compare the efficacy of the an N-acetyl-p-aminophenol (APAP, also known as acetaminophen) and N-acetylcysteine (NAC) combination versus an APAP-placebo combination as an anti-pyretic agent.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Geographic Reach
1 country

1 active site

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2009

Completed
1.2 years until next milestone

First Submitted

Initial submission to the registry

June 3, 2010

Completed
1 day until next milestone

First Posted

Study publicly available on registry

June 4, 2010

Completed
Last Updated

March 5, 2015

Status Verified

March 1, 2015

First QC Date

June 3, 2010

Last Update Submit

March 3, 2015

Conditions

Keywords

AcetaminophenAcetylcysteineAntidotes

Outcome Measures

Primary Outcomes (1)

  • Difference in temperature reduction between participants who are administered combination N-acetyl-p-aminophenol and N-Acetylcysteine (APAP-NAC) versus combination APAP-placebo

    6 hours after study drug administration

Secondary Outcomes (1)

  • Difference in liver function tests after study drug administration between participants who are administered combination N-acetyl-p-aminophenol and N-Acetylcysteine (APAP-NAC) versus combination APAP-placebo

    Within 24 hours of study drug administration

Study Arms (2)

APAP and NAC combination

EXPERIMENTAL

N-acetyl-p-aminophenol and placebo (APAP-NAC) combination pill

Drug: APAP and NAC combination

APAP and Placebo combination

PLACEBO COMPARATOR

N-acetyl-p-aminophenol and placebo (APAP-placebo) combination pill

Drug: APAP and Placebo

Interventions

APAP 650mg and NAC 600mg combination oral tablet administered once

Also known as: APAP: n-acetyl-p-aminophenol; acetaminophen; Tylenol, NAC: n-acetylcysteine; Mucomyst
APAP and NAC combination

APAP 650mg and Placebo combination oral tablet administered once

Also known as: APAP: n-acetyl-p-aminophenol; acetaminophen; Tylenol
APAP and Placebo combination

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • adults aged 18 to 75 years old
  • admitted to an inpatient unit at Columbia-Presbyterian Medical Center
  • fever defined as an oral temperature of 38.5°C

You may not qualify if:

  • if oral temperature cannot be obtained
  • abnormal aminotransferase levels
  • prior adverse reaction to acetaminophen or N-acetylcysteine

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Columbia University Medical Center

New York, New York, 10032, United States

Location

Related Publications (3)

  • Bronstein AC, Spyker DA, Cantilena LR Jr, Green J, Rumack BH, Heard SE. 2006 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS). Clin Toxicol (Phila). 2007 Dec;45(8):815-917. doi: 10.1080/15563650701754763.

    PMID: 18163234BACKGROUND
  • Smilkstein MJ, Knapp GL, Kulig KW, Rumack BH. Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdose. Analysis of the national multicenter study (1976 to 1985). N Engl J Med. 1988 Dec 15;319(24):1557-62. doi: 10.1056/NEJM198812153192401.

    PMID: 3059186BACKGROUND
  • Vale JA, Proudfoot AT. Paracetamol (acetaminophen) poisoning. Lancet. 1995 Aug 26;346(8974):547-52. doi: 10.1016/s0140-6736(95)91385-8. No abstract available.

    PMID: 7658783BACKGROUND

Related Links

MeSH Terms

Conditions

Liver FailureLiver Failure, AcuteChemical and Drug Induced Liver InjuryFever

Interventions

AcetaminophenAcetylcysteine

Condition Hierarchy (Ancestors)

Hepatic InsufficiencyLiver DiseasesDigestive System DiseasesDrug-Related Side Effects and Adverse ReactionsChemically-Induced DisordersPoisoningBody Temperature ChangesSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

AcetanilidesAnilidesAmidesOrganic ChemicalsAniline CompoundsAminesCysteineAmino Acids, SulfurSulfur CompoundsAmino AcidsAmino Acids, Peptides, and Proteins

Study Officials

  • Matthew Chang, MD

    Columbia University

    PRINCIPAL INVESTIGATOR
0

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 3, 2010

First Posted

June 4, 2010

Study Start

April 1, 2009

Last Updated

March 5, 2015

Record last verified: 2015-03

Locations